Clinical Trial Update: A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating SHR-1701 with and without famitinib in extensive-stage small cell lung cancer (SCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Famitinib (Famitinib)
• SHR-1701

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Lung Cancer | Phase 2 | Status: UNKNOWN